Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Aug 6th, 2026

Shares of Vericel Corporation (NASDAQ:VCEL – Get Free Report) have received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $58.40.

Several brokerages have weighed in on VCEL. Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, July 31st. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. TD Cowen upped their price target on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group set a $60.00 price objective on Vericel in a report on Thursday, July 30th. Finally, HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Vericel in a research note on Tuesday, July 28th.

View Our Latest Stock Report on Vericel

Insider Buying and Selling at Vericel

In related news, insider Jonathan Mark Hopper sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $45.00, for a total transaction of $450,000.00. Following the sale, the insider directly owned 75,753 shares in the company, valued at approximately $3,408,885. This represents a 11.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Siegal sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $48.90, for a total transaction of $220,050.00. Following the completion of the transaction, the insider directly owned 1,078 shares of the company’s stock, valued at approximately $52,714.20. This trade represents a 80.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 52,232 shares of company stock worth $2,304,217 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Vericel

A number of hedge funds and other institutional investors have recently bought and sold shares of VCEL. GW&K Investment Management LLC lifted its stake in Vericel by 22.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,580,967 shares of the biotechnology company’s stock worth $56,931,000 after purchasing an additional 290,795 shares in the last quarter. Granite Investment Partners LLC boosted its holdings in Vericel by 66.6% in the 1st quarter. Granite Investment Partners LLC now owns 120,236 shares of the biotechnology company’s stock valued at $3,868,000 after purchasing an additional 48,056 shares during the period. Madison Asset Management LLC purchased a new position in shares of Vericel during the 4th quarter valued at $1,819,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Vericel by 2,152.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 45,885 shares of the biotechnology company’s stock valued at $1,652,000 after purchasing an additional 43,848 shares in the last quarter. Finally, Fisher Asset Management LLC increased its holdings in shares of Vericel by 10.6% in the fourth quarter. Fisher Asset Management LLC now owns 187,616 shares of the biotechnology company’s stock worth $6,756,000 after purchasing an additional 18,002 shares during the period.

Vericel Stock Down 2.1%

VCEL opened at $45.36 on Thursday. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of 96.51 and a beta of 1.06. Vericel has a twelve month low of $28.95 and a twelve month high of $49.32. The company’s 50-day moving average price is $42.63 and its two-hundred day moving average price is $37.57.

Vericel (NASDAQ:VCEL – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $77.46 million during the quarter, compared to analyst estimates of $72.70 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.01) EPS. As a group, sell-side analysts anticipate that Vericel will post 0.54 earnings per share for the current year.

Vericel Company Profile

(Get Free Report)

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.